Additionally, the analysis reveals that drugs approved to treat either leukaemia or Kaposi’s sarcoma cluster, share the topoisomerase II alpha (TOP2A) enzyme as target (Fig. 3c). The gene discussed is TOP2A; the disease is leukemia.